| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Felix B. Engel | Q38327261 |
| P2093 | author name string | Tatyana Novoyatleva | |
| Amna Sajjad | |||
| P2860 | cites work | Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension | Q83822346 |
| TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кB pathway | Q84067885 | ||
| Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro | Q84570179 | ||
| Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury | Q85167906 | ||
| Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association | Q22306356 | ||
| A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis | Q24291951 | ||
| The receptor for the cytotoxic ligand TRAIL | Q24310481 | ||
| TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules | Q24553352 | ||
| Evidence for cardiomyocyte renewal in humans | Q24594522 | ||
| Epidemiology and risk profile of heart failure | Q24630778 | ||
| TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration | Q24670970 | ||
| The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas | Q24681487 | ||
| The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors | Q24684139 | ||
| TWEAK induces angiogenesis and proliferation of endothelial cells | Q28139175 | ||
| The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration | Q28146243 | ||
| The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 | ||
| Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth | Q28211919 | ||
| Multiple pathways of TWEAK-induced cell death | Q28214614 | ||
| A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation | Q28238947 | ||
| High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal | Q28242907 | ||
| An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
| Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin | Q28249401 | ||
| Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases | Q40763529 | ||
| The collagen network of the heart | Q41458239 | ||
| Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart | Q41518012 | ||
| Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation | Q41862491 | ||
| Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis | Q42269363 | ||
| Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial | Q42943898 | ||
| Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL | Q28250747 | ||
| TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis | Q28257134 | ||
| Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome | Q28266821 | ||
| TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling | Q28267294 | ||
| HMGB1 and RAGE in inflammation and cancer | Q28274621 | ||
| Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity | Q28299330 | ||
| Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies | Q28592715 | ||
| CD40 regulates the processing of NF-kappaB2 p100 to p52 | Q28610678 | ||
| Missing pieces in the NF-kappaB puzzle | Q29547864 | ||
| Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation | Q29617419 | ||
| NF-kappaB at the crossroads of life and death | Q29619302 | ||
| Transient regenerative potential of the neonatal mouse heart | Q29620371 | ||
| Type 2 diabetes across generations: from pathophysiology to prevention and management | Q30404232 | ||
| A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure | Q30496163 | ||
| Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. | Q30523246 | ||
| TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. | Q31148506 | ||
| Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline | Q33160867 | ||
| TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses | Q33352379 | ||
| The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review | Q33359478 | ||
| Fibroblast growth factor-inducible 14 (Fn14) is expressed in the lower genital tract and may play a role in amplifying inflammation during infection. | Q33624326 | ||
| B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction | Q33704093 | ||
| Stress pathways and heart failure | Q33734297 | ||
| Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation | Q33757338 | ||
| Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling | Q33862454 | ||
| Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart | Q33907789 | ||
| TWEAK induces liver progenitor cell proliferation | Q33919951 | ||
| The noncanonical NF-κB pathway | Q34031207 | ||
| The molecular architecture of the TNF superfamily | Q34109796 | ||
| RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF | Q34167602 | ||
| Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways | Q34173731 | ||
| Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice | Q34270015 | ||
| Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human | Q34503355 | ||
| PGC1α plays a critical role in TWEAK-induced cardiac dysfunction | Q34559082 | ||
| A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia | Q35083662 | ||
| T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation | Q35754623 | ||
| Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. | Q43191172 | ||
| TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy. | Q43854231 | ||
| MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure | Q43880520 | ||
| TWEAK is a positive regulator of cardiomyocyte proliferation | Q44200357 | ||
| Functional expression of TWEAK in human colonic adenocarcinoma cells. | Q45178812 | ||
| FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. | Q45921112 | ||
| Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction | Q46990548 | ||
| Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. | Q47341057 | ||
| The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily | Q48003125 | ||
| Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure | Q48421210 | ||
| TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia | Q48474315 | ||
| Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. | Q50752354 | ||
| Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. | Q51576481 | ||
| Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. | Q51754844 | ||
| NF-kappaB signaling. Many roads lead to madrid. | Q52601425 | ||
| BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. | Q53664665 | ||
| Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. | Q54350603 | ||
| Inhibition of IκB phosphorylation prevents load-induced cardiac dysfunction in mice. | Q54479213 | ||
| Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. | Q54534373 | ||
| Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. | Q54562352 | ||
| Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. | Q54653388 | ||
| Involvement of CD95/Apo1/Fas in Cell Death After Myocardial Ischemia | Q57384620 | ||
| Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure | Q58071197 | ||
| Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction | Q59981285 | ||
| Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction | Q60607085 | ||
| Tumor Necrosis Factor–Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in ApoE-Knockout Mice | Q63684391 | ||
| Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration | Q63988279 | ||
| Collagen chain mRNAs in isolated heart cells from young and adult rats* | Q68453362 | ||
| Elevated circulating levels of tumor necrosis factor in severe chronic heart failure | Q68524243 | ||
| Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization | Q69601713 | ||
| Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart | Q71102878 | ||
| Cardiomyocyte DNA synthesis and binucleation during murine development | Q71839305 | ||
| Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collabo | Q72665772 | ||
| TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity | Q73075512 | ||
| Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes | Q73120309 | ||
| Congestive heart failure: fifty years of progress | Q73194427 | ||
| Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies | Q73287081 | ||
| Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha | Q73742574 | ||
| Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy | Q74180444 | ||
| TWEAK stimulation of astrocytes and the proinflammatory consequences | Q74280324 | ||
| Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure | Q74292256 | ||
| Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor | Q74364510 | ||
| Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats | Q74522770 | ||
| Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis | Q79287547 | ||
| TWEAK is a novel arthritogenic mediator | Q80058054 | ||
| Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes | Q80665048 | ||
| Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy | Q81318870 | ||
| Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure | Q81730161 | ||
| Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia | Q35893298 | ||
| Duality of innate stress responses in cardiac injury, repair, and remodeling | Q35893782 | ||
| Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling | Q35926510 | ||
| Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer | Q36230448 | ||
| The history of matrix metalloproteinases: milestones, myths, and misperceptions | Q36312509 | ||
| Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells | Q36469716 | ||
| Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction | Q36683886 | ||
| Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression | Q36699619 | ||
| Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets | Q36732005 | ||
| Reconstitution of the myocardium in regenerating newt hearts is preceded by transient deposition of extracellular matrix components | Q36936881 | ||
| Molecular regulation of autophagy and apoptosis during ischemic and non-ischemic cardiomyopathy | Q37119596 | ||
| The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting | Q37135363 | ||
| Proinflammatory consequences of transgenic fas ligand expression in the heart | Q37194997 | ||
| Features of cardiomyocyte proliferation and its potential for cardiac regeneration. | Q37228759 | ||
| Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death | Q37362206 | ||
| TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure | Q37771751 | ||
| Endogenous toll-like receptor ligands and their biological significance | Q37772578 | ||
| When are pro-inflammatory cytokines SAFE in heart failure? | Q37838085 | ||
| Pharmacological strategies for lowering LDL cholesterol: statins and beyond | Q37842120 | ||
| The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? | Q37864469 | ||
| Multiple facets of NF-κB in the heart: to be or not to NF-κB. | Q37870038 | ||
| Dietary factors associated with hypertension | Q37897475 | ||
| Antiplatelet therapy, cardiac surgery, and the risk of bleeding: the surgeon's perspective | Q37955779 | ||
| Therapeutic role of toll-like receptor modification in cardiovascular dysfunction | Q38052410 | ||
| Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities | Q38053492 | ||
| Insights into the activity, differential expression, mutual regulation, and functions of matrix metalloproteinases and a disintegrin and metalloproteinases in hypertension and cardiac disease | Q38061567 | ||
| The cardiomyocyte cell cycle in hypertrophy, tissue homeostasis, and regeneration. | Q38100672 | ||
| The TWEAK-Fn14 system as a potential drug target | Q38129961 | ||
| Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. | Q38495982 | ||
| HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes | Q39216682 | ||
| Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway | Q39683156 | ||
| Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. | Q40320063 | ||
| Tweak induces mammary epithelial branching morphogenesis. | Q40453290 | ||
| Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. | Q40479943 | ||
| Involvement of GSK-3beta in TWEAK-mediated NF-kappaB activation | Q40555106 | ||
| Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis | Q40555742 | ||
| TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors | Q40644972 | ||
| P304 | page(s) | 50 | |
| P577 | publication date | 2014-02-11 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure | |
| P478 | volume | 5 |
| Q41834760 | Association between miR-181b and PKG 1 in myocardial hypertrophy and its clinical implications |
| Q38748557 | Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases |
| Q89441236 | Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease |
| Q51739158 | Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults. |
| Q60952877 | Fn14 Deficiency Ameliorates Anti-dsDNA IgG-Induced Glomerular Damage in SCID Mice |
| Q35857296 | Fn14, a Downstream Target of the TGF-β Signaling Pathway, Regulates Fibroblast Activation |
| Q55155611 | Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. |
| Q43169774 | Regulation of Tissue Responses: The TWEAK/Fn14 Pathway and Other TNF/TNFR Superfamily Members That Activate Non-Canonical NFκB Signaling |
| Q36848839 | Serum Levels of TNF Receptor Ligands Are Dysregulated in Sepsis and Predict Mortality in Critically Ill Patients |
| Q33578212 | Silent disease progression in clinically stable heart failure |
| Q27347256 | Soluble Fn14 Is Detected and Elevated in Mouse and Human Kidney Disease |
| Q89454322 | TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart |
| Q41669201 | TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy |
| Q38741719 | TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner |
| Q42361200 | TWEAK/Fn14 Activation Participates in Skin Inflammation |
| Q34309016 | The relationship between asymptomatic organ damage, and serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and Interleukin-17A (IL-17A) levels in non-diabetic hypertensive patients |
| Q99594107 | Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B |
| Q89696547 | Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges |
Search more.